[Note: Shared for #AutisticHistory archive purposes. This is NOT An Autistic Ally.]
CARA Clears First Vote In Congress
May 28, 2014
WASHINGTON, DC (May 28, 2014) — A House panel today quickly approved the Combating Autism Reauthorization Act (CARA), HR.4631, adopting amendments worked out with supporters in the Senate.
The voice voteby the House Energy and Commerce Subcommittee on Health, chaired by Rep. Joe Pitts R-PA) left, was the first on the bill since it was introduced May 12 by Reps. Chris Smith (R-NJ) and Mike Doyle (D-PA). The bill now goes before the full House Energy and Commerce Committee.
View the hearing below
“Today’s subcommittee markup was an important first step towards passing a very important piece of legislation,” said Stuart Spielman, senior policy advisor and counsel, Autism Speaks. “We must protect the federal investment in autism and ensure that it is as efficient and effective as possible going forward. We look forward to working with the House and Senate to ensure the best bill possible is signed into law to address this crisis.”
The Combating Autism Act, enacted in 2006 and then renewed in 2011, will expire September 30 unless reauthorized by Congress. The law has dedicated $1.7 billion in federal funding for autism research, prevalence monitoring and training of medical professionals.
“In addition to reauthorizing existing provisions, the bill will require a study on the needs of autistic youth transitioning into adulthood and the available services to help them as adults” said Pitts. “We have worked closely with our Senate colleagues to strengthen this bill and continue the important research to identify better prevention strategies, diagnostics, treatments, and even a cure.”
Rep. Fred Upton (R-MI), who chairs the full House Energy and Commerce Committee, said, “In the face of growing prevalence, it is critical that we continue to support those with Autism Spectrum Disorders and their families by supporting autism research and passing H.R. 4631.”
Since the law was first enacted in 2006, the prevalence of autism has jumped 123 percent.
The ranking Democrat on the subcommittee, Rep. Frank Pallone, said, “Extending the current programs already underway is still critical….The amendment reflects ongoing bipartisan and bicameral efforts to achieve consensus legislation.”
Pallone said House supporters are working closely with Senators Tom Harkin (D-IA), Lamar Alexander (R-TN), Robert Menendez (D-NJ) and Mike Enzi (R-WY) “to ensure the bill moves forward expeditiously.”
Pallone Statement from Health Subcommittee Markup
May 28, 2014
WASHINGTON, D.C.—Congressman Frank Pallone, Jr. (NJ-06), senior Democrat on the House Energy and Commerce Health Subcommittee, issued the following statement today at a markup on three bills, H.R. 4299, “Improving Regulatory Transparency for New Medical Therapies Act,” H.R. 4709, “Ensuring Patient Access and Effective Drug Enforcement Ac,” and H.R. 4631, “Combating Autism Reauthorization Act of 2014.”
Today we are marking up three important bipartisan health bills.
I am proud to join with you, Chairman Pitts on H.R. 4299, “Improving Regulatory Transparency for New Medical Therapies Act.” The bill aims to improve the DEA scheduling process for new FDA-approved drugs under the Controlled Substances Act and the registration process for the use of controlled substances in clinical trials.
Without weakening FDA oversight, this Committee has worked together, most recently on FDASIA, to give manufacturers and patient groups a more predictable process, allowing patients to get timely access to the latest innovation therapies available. Unfortunately, we have learned that when a medicine has abuse potential, the DEA’s authorities under the Controlled Substances Act are hindering this progress.
Our bill would require DEA to make a final determination 45 days after receiving FDA’s scheduling recommendation for a new drug. Additionally, it would generate greater transparency in the application process for drug makers who want to manufacture drugs for clinical trials.
We all agree DEA has an important role to play in combatting the abuse and diversion of drugs. But in examining this problem during our Subcommittee hearing, it seems to me that there is an unnecessarily repetitive process at the DEA for brand new products. As a result, there is a delay of critical drugs getting to patients who need them. I hope members will support this common sense correction to DEA authorities.
In addition, we will markup H.R. 4709, “the Ensuring Patient Access and Effective Drug Enforcement Act of 2014.” This is an updated version of a bill the Subcommittee examined in April. The bill aims to improve and better coordinate enforcement efforts within the drug supply chain regarding prescription drug diversion and abuse.
Prescription drug abuse threatens the safety and health of too many people in this country. Like the Pitts-Pallone bill, the goal of this legislation is not to impede DEA’s critical mission of catching bad actors who break laws and divert dangerous drugs. However, by creating a more collaborative partnership between drug manufacturers, wholesalers, retail pharmacies, and the DEA, the bill seeks to limit unnecessary supply chain disruptions that may be affecting patient access to needed medications.
Specifically, it would allow supply chain members an opportunity to submit a corrective action plan prior to having their license revoked or suspended by DEA. It also requires a report to Congress on the impact of enforcement activities and opportunities for agency and stakeholder collaboration to combat prescription drug abuse.
Lastly, I am pleased to support H.R. 4631, the “Combating Autism Reauthorization Act of 2014.” Established over a decade ago, this longtime bipartisan effort was a direct response to the rising concern about the increased prevalence of autism in this country. In fact, the most recent report by the Centers for Disease Control and Prevention (CDC) on the prevalence of autism says that 1 in 68 children have autism. This new estimate is roughly 30 percent higher than the estimate for 2008. Meanwhile, in my home state of New Jersey, 1 in 45 children have autism. Now, we don’t know what one factor is causing this increase. Some of it may be due to the way children are identified, diagnosed, and served in their local communities, but exactly how much is unknown.
That is why extending the current programs already underway is still critical. These programs include research and surveillance activities, education, early detection, and intervention efforts and the work of the Interagency Autism Coordinating Committee. In addition, today we will consider a manager’s amendment with a number of updates to current law. The amendment reflects ongoing bipartisan and bicameral efforts to achieve consensus legislation.
I want to commend Congressman Smith and Congressman Doyle for sponsoring this legislation. I also want to acknowledge the ongoing efforts of our Senate colleagues — Senators Harkin, Alexander, Menendez, and Enzi – who continue to work with our staff and the staff of Congressman Smith and Congressman Doyle to ensure the bill moves forward expeditiously. I look forward to working with everyone to accomplish that goal.
The Autism Community Is Not The Autistic Community
More With Autism Votes
Autistic people have fought the inclusion of ABA in therapy for us since before Autism Speaks, and other non-Autistic-led autism organizations, started lobbying legislation to get it covered by insurances and Medicaid.
ABA is a myth originally sold to parents that it would keep their Autistic child out of an institution. Today, parents are told that with early intervention therapy their child will either be less Autistic or no longer Autistic by elementary school, and can be mainstreamed in typical education classes. ABA is very expensive to pay out of pocket. Essentially, Autism Speaks has justified the big price tag up front will offset the overall burden on resources for an Autistic’s lifetime. The recommendation for this therapy is 40 hours a week for children and toddlers.
The original study that showed the success rate of ABA to be at 50% has never been replicated. In fact, the study of ABA by United States Department of Defense was denounced as a failure. Not just once, but multiple times. Simply stated: ABA doesn’t work. In study after repeated study: ABA (conversion therapy) doesn’t work.
What more recent studies do show: Autistics who experienced ABA therapy are at high risk to develop PTSD and other lifelong trauma-related conditions. Historically, the autism organizations promoting ABA as a cure or solution have silenced Autistic advocates’ opposition. ABA is also known as gay conversion therapy.
The ‘cure’ for Autistics not born yet is the prevention of birth.
The ‘cure’ is a choice to terminate a pregnancy based on ‘autism risk.’ The cure is abortion. This is the same ‘cure’ society has for Down Syndrome.
This is eugenics 2021. Instead of killing Autistics and disabled children in gas chambers or ‘mercy killings’ like in Aktion T4, it’ll happen at the doctor’s office, quietly, one Autistic baby at a time. Different approaches yes, but still eugenics and the extinction of an entire minority group of people.
Fact: You can’t cure Autistics from being Autistic.
Fact: You can’t recover an Autistic from being Autistic.
Fact: You can groom an Autistic to mask and hide their traits. Somewhat. … however, this comes at the expense of the Autistic child, promotes Autistic Burnout (this should not be confused with typical burnout, Autistic Burnout can kill Autistics), and places the Autistic child at high risk for PTSD and other lifelong trauma-related conditions.
[Note: Autism is NOT a disease, but a neurodevelopmental difference and disability.]
Fact: Vaccines Do Not Cause Autism.